Inducible Co-stimulator Gene With Systemic Lupus Erythematosus
NCT07675837 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2026-06-30
Summary
The aim of this study is to investigate the association between ICOS gene polymorphism and susceptibility to systemic lupus erythematosus (SLE), as well as its impact on disease severity.
Conditions
- Systemic Lupus Erthematosus
Sponsors & Collaborators
-
South Valley University
lead OTHER
Principal Investigators
-
Eisa Mohammed Hegazy, Professor · Dermatology, Venereology & Andrology Department ,Faculty of Medicine ,South Valley University.
-
Mohammed Hosny Hassan, Professor · Biochemistry , Qena faculty of medicine ,south valley university.
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-06-30
- Primary Completion
- 2027-06-30
- Completion
- 2027-07-31
Countries
- Egypt
Study Locations
More Related Trials
-
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
NCT07629583 ·Status: RECRUITING ·Phase: PHASE1
-
Interleukin23 in Systemic Lupus
NCT06713187 ·Status: RECRUITING ·Phase: NA
-
An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)
NCT00960362 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus
NCT06137053 ·Status: RECRUITING
-
Efficacy and Safety of Telitacicept in Early SLE
NCT05899907 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Disease Activity and Organ Damage
NCT04558814 ·Status: UNKNOWN ·Phase: NA
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
NCT02535689 ·Status: COMPLETED ·Phase: PHASE1
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
NCT01689350 ·Status: COMPLETED ·Phase: NA
-
New Signaling Pathway Targeting Systemic Lupus Erythematosus
NCT03984227 ·Status: UNKNOWN
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants
NCT05278663 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
NCT06857214 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital
NCT06491602 ·Status: RECRUITING
-
Safety of IFNa Kinoid in Systemic Lupus Erythematosus
NCT01058343 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus
NCT07538154 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
NCT06167174 ·Status: RECRUITING
-
Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)
NCT06458972 ·Status: RECRUITING
-
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
NCT05866861 ·Status: COMPLETED ·Phase: PHASE1
-
The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus Patients
NCT06313151 ·Status: RECRUITING
-
AntiDFS70 Lupus Nephritis
NCT06119763 ·Status: RECRUITING
-
A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
NCT02908100 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
NCT05638802 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Expression of CXCR4 in Patients With Systemic Lupus Erythematosus
NCT04799730 ·Status: UNKNOWN
-
Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study
NCT00271934 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
NCT03252587 ·Status: COMPLETED ·Phase: PHASE2